998P A phase I study of CKD-702, an EGFR-cMET bispecific antibody, in advanced or metastatic non-small cell lung cancer (NSCLC)

医学 双特异性抗体 肿瘤科 内科学 非小细胞肺癌 临床研究阶段 抗体 癌症研究 肺癌 化疗 单克隆抗体 免疫学 A549电池
作者
Dongwook Kim,SH Lee,I-J. Jang,K-J. Park,D.H. Lee
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:33: S1010-S1010 被引量:1
标识
DOI:10.1016/j.annonc.2022.07.1124
摘要

CKD-702 binds simultaneously to cMET and EGFR and inhibits cancer cell proliferation. Here we report the safety, pharmacokinetic (PK), pharmacodynamic (PD) and preliminary efficacy of CKD-702 from the dose escalation part of a phase I study in patients (pts) with advanced/metastatic NSCLC. Pts received intravenous (IV) CKD-702 once every 2 weeks (q2w) using a 3+3 design in 4 escalating doses from 10 mg/kg to 25 mg/kg until progression or unacceptable toxicity. After evaluating dose-limiting toxicity (DLT) at all planned dose levels, additional pts were enrolled at the 3rd and 4th dose levels for safety and PK analysis. Molecular changes were analyzed during the screening period using ctDNA and/or tumor tissue. At data cut-off (3 Feb 2022), 24 pts were enrolled and received CKD-702. No DLT was reported at any dose level; ≥1 treatment-emergent AEs (TEAEs) occurred in all 24 pts. Common (≥20%) all-grade (Gr) AEs were rash, paronychia, stomatitis, nausea, and hypoalbuminemia. Infusion related reactions (21%) were all Gr 1-2. AEs ≥Gr 3 occurred in 41.67% of pts; 3 pts reported Gr 3 rash (2 maculopapular, 1 acneiform). CKD-702 exposure and half-life increased in a dose-related manner; accumulation (∼1.3×) was confirmed upon repeat-dosing. EGFR-extracellular domain (ECD) tended to increase ∼2-fold regardless of CKD-702 dose; cMET-ECD increased dose-dependently to 20 mg/kg with estimated saturation >20 mg/kg. Among 24 response-evaluable pts, 5 achieved a best time point response of partial response (PR) including 2 confirmed PR: 3 MET ex14 skipping, 1 MET IHC 3+ with EGFR exon 19 deletion, and 1 EGFR L858R with no identified MET-alteration. Among 6 pts with Met ex14 skipping (4 cMET TKI-naïve and 2 cMET TKI-resistant), 3 (all of cMET TKI-naïve) had a best time point response of PR including 2 confirmed. The recommended phase II dose was determined to be 20 mg/kg based on safety, PK, and PD review. CKD-702 has a manageable safety profile related to EGFR and cMet inhibition, and showed preliminary response in patients with MET ex14 skipping. Part 2 (dose expansion) will use IV CKD-702 20 mg/kg q2w; the planned cohort includes MET-alteration NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
木木 12完成签到,获得积分10
刚刚
文静凝芙完成签到,获得积分10
刚刚
活泼雪莲发布了新的文献求助10
1秒前
可乐大侠完成签到 ,获得积分10
1秒前
萌萌2完成签到,获得积分10
1秒前
慈祥的鸿煊完成签到 ,获得积分10
2秒前
fantasy的应助被369ninja采纳,获得10
3秒前
王不凡完成签到 ,获得积分10
3秒前
Jeffrey完成签到,获得积分10
3秒前
蝈蝈完成签到,获得积分10
4秒前
雪山大地发布了新的文献求助10
5秒前
Echo完成签到,获得积分0
8秒前
JIANG完成签到,获得积分10
10秒前
ARIA完成签到 ,获得积分0
10秒前
群山完成签到 ,获得积分10
11秒前
mongmong完成签到 ,获得积分10
12秒前
13秒前
春夏完成签到 ,获得积分10
13秒前
卢彦冬完成签到,获得积分10
15秒前
16秒前
冷静以山完成签到 ,获得积分10
20秒前
飞儿完成签到 ,获得积分10
22秒前
369ninja发布了新的文献求助10
22秒前
兴奋的惮完成签到,获得积分10
23秒前
进击的牛马完成签到,获得积分10
23秒前
游01完成签到 ,获得积分10
25秒前
打打的应助被活泼雪莲采纳,获得10
27秒前
zhuangbaobao完成签到,获得积分10
27秒前
28秒前
个性怡完成签到 ,获得积分10
28秒前
深情的乐萱完成签到,获得积分10
28秒前
雪山大地发布了新的文献求助10
30秒前
失眠的寄云完成签到,获得积分10
33秒前
33秒前
O_0完成签到 ,获得积分10
33秒前
WQ完成签到,获得积分10
33秒前
莹莹大王发布了新的文献求助10
38秒前
落月无痕完成签到,获得积分10
40秒前
win050532完成签到 ,获得积分10
41秒前
吃饭打肯德基完成签到 ,获得积分10
43秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166550
求助须知:如何正确求助?哪些是违规求助? 9559535
关于积分的说明 21750720
捐赠科研通 7757357
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553523
邀请新用户注册赠送积分活动 2473904